Novo Nordisk is going to spend billions of dollars to make its production facilities in France bigger
Novo Nordisk has announced its intention to allocate a substantial investment exceeding DKK 16 billion (equivalent to US$2.3 billion) towards the expansion of its production facilities located in Chartres, France.
On November 23, 2023, Novo Nordisk made a significant declaration regarding its intention to allocate a substantial sum of DKK 16 billion (equivalent to US$2.3 billion) towards the expansion of its current production facility situated in Chartres, France. This investment is set to commence in the year 2023. The company intends to enhance the manufacturing site's capacity by incorporating aseptic production and finished production procedures. Additionally, there are plans to extend the existing laboratory for quality control purposes.
With the implementation of the enhanced facilities, the physical area occupied by the site will undergo a substantial increase, surpassing its original size by more than two-fold. According to a press release issued by the company, the investment encompasses the provision for products containing glucagon-like peptide-1. The commencement of construction endeavors for the expansion initiatives has been initiated, with a gradual culmination expected to occur within the timeframe spanning from 2026 to 2028. Upon the completion of the construction, it is anticipated that over 500 new employment opportunities will be generated, and the production operations are expected to operate continuously, round the clock.
The announcement of this substantial investment serves to reaffirm the significance of our French manufacturing facility, which stands as a pivotal production site within our strategic framework. It underscores the pivotal role it plays in driving the growth trajectory we are currently witnessing as an organization. "In an effort to optimize our existing site resources and capabilities, we are strategically enhancing our operational capacity," stated Lone Charlotte Larsen, the esteemed corporate vice-president of Novo Nordisk Production Chartres, as expressed in the official press release.
Henrik Wulff, the executive vice-president of Product Supply, Quality & IT at Novo Nordisk, expressed our strong confidence in our present and future product portfolio's significance for individuals grappling with severe chronic ailments. This is evident through our ongoing commitment to enhancing our manufacturing facilities worldwide.
Source: Novo Nordisk
